VRDN

30.3303.53%
RT

Radhika Tripuraneni

Chief Medical Officer

Dr. Radhika Tripuraneni, M.D. M.P.H., is Chief Medical Officer of Viridian Therapeutics, Inc. from March 10, 2025. She was an Independent Director of Terns Pharmaceuticals, Inc. from July 2022 until May 4, 2026. She was Chief Development Officer at Prothena Corporation plc. from December 2018 until September 2022. Dr. Tripuraneni served as Vice President of Medical Affairs & Development Operations at Prothena Corp. plc since 2018. Prior to joining Prothena, Dr. Tripuraneni was Vice President, Medical Affairs and Chief of Staff to the Chief Medical Officer of MyoKardia Inc. Dr. Tripuraneni served as Vice President of Medical Affairs at MyoKardia, Inc. since February 1, 2017 until 2018. Dr. Tripuraneni served as Vice President of Medical Affairs at Synageva BioPharma (later Alexion Pharmaceuticals). Dr. Tripuraneni has experience across multiple therapeutic areas, including rare and cardiovascular diseases, with particularly valuable expertise building medical affairs teams in diseases where no approved therapies exist. She served as a Cardiovascular Medical Director at Gilead Sciences Inc. and Global Medical Director & Global Medical Affairs Lead for two therapeutic areas at Genzyme Corporation. She did her surgical internship at Beth Israel Deaconess Medical Center in Boston, a major teaching hospital of Harvard Medical School. Dr. Tripuraneni holds Bachelor’s degrees in business administration and Liberal Arts and an M.D. degree from The University of Missouri. Dr. Tripuraneni earned her Master,s in Public Health from Harvard University. She did her clinical training in general surgery at Harvard - Beth Israel Deaconess Medical Center.

Positions